



Date: 29 March 2018

Sydney, Australia

**ASX: NOX**

**Noxopharm Limited**

ABN 50 608 966 123

**Registered Office:**

Suite 3, Level 4  
828 Pacific Highway  
Gordon NSW 2072  
Australia

**Operational Office:**

Suite 3, Level 4  
828 Pacific Highway  
Gordon NSW 2072  
Australia

**Board of Directors**

**Mr Peter Marks**

Chairman  
Non-Executive  
Director

**Dr Graham Kelly**

Chief Executive Officer  
Managing Director

**Dr Ian Dixon**

Non-Executive  
Director

ASX Limited  
20 Bridge Street  
SYDNEY NSW 2000

**NOTICE UNDER SECTION 708A(5)(E) OF THE CORPORATIONS ACT 2001 (CTH)**

Noxopharm Limited (ASX: NOX) (**Noxopharm** or the **Company**) has today issued 7,264,966 new fully paid ordinary shares in the Company (**New Shares**) to Sophisticated and Professional Investors, at an issue price of A\$0.90 per New Share. The New Shares were issued under the Private Placement detailed in the ASX announcement ASX on 23 March 2018.

Please see attached Appendix 3B for more details.

NOX gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) that:

- 1 The New Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act.
- 2 As at the date of this notice, NOX has complied with:
  - (a) The provisions of Chapter 2M of the Corporations Act as they apply to NOX; and
  - (b) Section 674 of the Corporations Act.
- 3 As at the date of this notice, there is no information that is "excluded information" of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act that is required to be disclosed by the Company under section 708A(6)(e) of the Corporations Act.

For and on behalf of the Board,

Yours faithfully,

David Franks  
Company Secretary